Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia

Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25.

Authors

Salem Bahashwan^{1

2}, Cécile Moluçon-Chabrot^{1

2}, Eric Hermet^{1

2}, Aurélie Ravinet^{1

2}, Aurore Douge^{1

2}, Lauren Veronese^{1

3}, Andrei Tchirkov^{1

3}, Richard Lemal^{1

2}, Marc G Berger^{1

4}, Richard Veyrat-Masson^{1

4}, Olivier Tournilhac^{1

2}, Jacques-Olivier Bay^{1

2}, Romain Guièze^{1

2}

Affiliations

¹ Clermont Auvergne University, Clermont-Ferrand, France.
² Unit of Adult Cell Therapy and Clinical Hematology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
³ Cytogenetic Laboratory, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
⁴ Department of Biology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

PMID: 30370957
DOI: 10.1002/ajh.25332

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aminoglycosides / administration & dosage
Aminoglycosides / adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Combined Modality Therapy
Cytarabine / administration & dosage
Cytarabine / adverse effects
Disease-Free Survival
Female
Gemtuzumab
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy
Male
Middle Aged
Mitoxantrone / administration & dosage
Mitoxantrone / adverse effects
Recurrence
Salvage Therapy*
Treatment Outcome
Young Adult

Substances

Aminoglycosides
Antibodies, Monoclonal, Humanized
Cytarabine
Gemtuzumab
Mitoxantrone